Yüklüyor......
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
Ruxolitinib (INCB018424) is a JAK1 and JAK2 inhibitor recently evaluated for the treatment of myelofibrosis (MF) in early- and advanced-phase clinical trials. In 2 recent communications that focused on short-term and long-term ruxolitinib treatment outcome, respectively, the drug was shown to be eff...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Mayo Foundation for Medical Education and Research
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228619/ https://ncbi.nlm.nih.gov/pubmed/22034658 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4065/mcp.2011.0518 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|